Skip to main content

United States News All stories

Every story in this section, newest first — page 193 of 373.

Grafa

Artiva Biotherapeutics secures FDA alignment for Phase 3 RA trial after strong Phase 2a results

Artiva Biotherapeutics (NASDAQ:ARTV) has reached a pivotal regulatory milestone, securing FDA alignment for a single Phase 3 registrational trial of its lead candidate, AlloNK, following positive initial data in refractory rheumatoid arthritis (RA).

Read more: Artiva Biotherapeutics secures FDA alignment for Phase 3 RA trial after strong Phase 2a results
Grafa

Creative Media & Community Trust reports multifamily growth amid strategic restructuring

Creative Media & Community Trust (NASDAQ:CMCT) reported operating results for the first quarter of 2026, characterized by a dual focus on operational improvement in residential assets and a sweeping overhaul of its capital structure.

Read more: Creative Media & Community Trust reports multifamily growth amid strategic restructuring